Incyte (INCY) has been quietly outperforming the broader biotech space this year, with the stock up about 46% over the past year and more than 40% year to date, drawing fresh attention. See our latest ...

Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in combination with Revlimid (lenalidomide) and rituximab, is now indicated ...

Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript July 29, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.04, expectations were $1.39. Operator: Greetings, and ...

Baker Brothers’ Q3 2025 13F portfolio rose to $13.84B, with high concentration in BeOne Medicines, Incyte, Madrigal Pharma, Insmed, and ACADIA Pharma. INCY, now ~19% of the portfolio, saw a marginal ...

Incyte (INCY) shares soared 5.5% in the last trading session to close at $102.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Incyte Corp. Annual stock financials by MarketWatch. View the latest INCY financial statements, income statements and financial ratios.

A collection of films following Peter Parker as he navigates adolescence while taking on the responsibilities of being Spider-Man in a world filled with superheroes. As Peter faces increasingly ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed.

Revealed as the web-slinging superhero, Peter Parker wants the world to forget, so he begs a spell from Dr Strange, but with grave consequences. Foes from across the multiverse materialise – along ...